Zimbabwe has declined a major American health deal valued at 367 million US dollars (272 million pounds) over five years due to the United States' request for sensitive biological samples.
This move became public after a official document dated December was leaked, indicating that Head of State Emmerson Mnangagwa deemed the deal was "skewed".
A government spokesman later clarified that the United States was seeking biological samples for research and commercial purposes while was unwilling to guarantee the resulting advantages from future vaccines.
"We must now begin the difficult and regrettable process of scaling back our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy said the US had provided more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has called for more talks to reach a deal suitable to both sides so the nation's vital HIV treatment initiative can proceed.
Wider Context
This development follows a comparable situation in Kenya, where a high court blocked a similar health funding agreement after concerns were filed about the security of citizens' health data.
After resuming office recently, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
USAID had administered aid for the American government, but Trump argued its spending was "inefficient" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
As per reports, 16 nations in Africa have so far agreed to similar agreements, constituting over $18.3bn in committed funds.
Details of the Declined Deal
This assistance for Zimbabwe would have gone towards "HIV/Aids treatment and prevention, TB, malaria, maternal and child health, and preparing for epidemics".
"We are confident this cooperation would have delivered significant benefits for Zimbabwean communities, particularly the 1.2 million men, women and children currently on antiretroviral therapy via American-funded initiatives," Tremont said.
However, government spokesperson Nick Mangwana argued the proposed deal was "asymmetrical".
"Zimbabwe was being asked to provide its biological resources and data indefinitely, without any equivalent guarantee of access to any medical innovations – like new medicines or tests – that could result from that shared data," his statement read.
"In essence, our nation would supply the raw materials for scientific discovery without any assurance that the end products would be available to our citizens if a new pandemic arise."
Sovereignty and International Frameworks
He also noted that the American exit from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were upending frameworks previously established via the global health agency.
Mangwana gave as an example its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This framework is designed to ensure that when a nation contributes its information, the benefits – such as vaccines and treatments – are shared equitably, not monopolised solely by those with the resources to develop them."
Zimbabwe's reservations regarding the US deal "must not be interpreted as anti-American sentiment," Mangwana stressed.
"We encourage further dialogue with our US partners on how subsequent collaboration could be structured in a manner that respects the sovereignty and interests of each country."
Medical Community Response
A leading public health body said it recognised the government's concerns, but suggested that negotiations must proceed considering a large portion of the country's Aids initiatives were funded by external financing.
"If technical issues arise, including those involving information security or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it commented.
This impasse underscores the ongoing tensions between receiving vital foreign assistance and safeguarding local interests in an ever more interconnected world.